According to the Zhitong Finance APP, CICC Securities released a research report stating that the target price of Tigermed (03347) listed in Hong Kong has been lowered by 16.8%, from HK$58.4 to HK$48.6, and reduced the earnings forecast per share for 2024-2026 by 7%-14% due to poor performance in the third quarter of 2024. However, they still maintain their "outperform" rating.

The report mentioned that Tigermed's third-quarter revenue and adjusted net profit decreased by 12% and 38% year-on-year, mainly due to customer payment pressure leading to corresponding accounts receivable write-offs; 2) due to the reallocation of interest income due to accounting policy changes. If these impacts (87 million RMB) are excluded, the adjusted net profit decreases by 16% year-on-year, remains flat quarter-on-quarter, and still falls below CICC Securities' expectations.